Great Point Partners’s BridgeBio Oncology BBOT Stock Holding History

Great Point Partners’s Portfolio BBOT Stock Details BBOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-29,381	Closed	-$312K	–	38
2025 Q2	$312K	Sell	29,381 -344,452	-92%	-$3.72M	0.2%	26
2025 Q1	$4.22M	Sell	373,833 -126,167	-25%	-$1.36M	2.24%	21
2024 Q4	$5.25M	Hold	500,000	–	–	2.47%	17
2024 Q3	$5.22M	Hold	500,000	–	–	1.54%	24
2024 Q2	$5.11M	Hold	500,000	–	–	0.98%	28
2024 Q1	$5.2M	Buy	+500,000	New	+$5.18M	0.81%	32

Other funds holding BBOT

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Great Point Partners's BBOT Position: Q3 2025 in Review

Great Point Partners sold out of BridgeBio Oncology (BBOT) in Q3 2025, closing a stake of 29,381 shares — an estimated $312K sold.

Great Point Partners first reported a position in BBOT in Q1 2024 and held it in 6 quarters. The position peaked at $5.25M in Q4 2024. 42 funds tracked by Wall St. Rank hold BBOT as of Q3 2025.

Great Point Partners reported no remaining BridgeBio Oncology position as of Q3 2025 after selling out during the quarter.
Great Point Partners sold 29,381 BridgeBio Oncology shares in Q3 2025, an estimated $312K.
Great Point Partners first reported a position in BridgeBio Oncology in Q1 2024 and held it in 6 quarters.
Great Point Partners's BridgeBio Oncology position peaked at $5.25M in Q4 2024.
42 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q3 2025.

Based on Great Point Partners's 13F filing for Q3 2025, filed 14 Nov 2025.